002589.SZ
Realcan Pharmaceutical Group Co., Ltd. [002589.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002589.SZ Stock Summary
Top 10 Correlated ETFs
002589.SZ
Top 10 Correlated Stocks
002589.SZ
In the News
002589.SZ Financial details
Company Rating
Neutral
Market Cap
4.16B
Income
-1.86B
Revenue
7.52B
Book val./share
3.64
Cash/share
3.72
Dividend
-
Dividend %
-
Employees
5.12K
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
-2.5
Forward P/E
-
PEG
0.04
P/S
0.62
P/B
0.85
P/C
0.66
P/FCF
-2.59
Quick Ratio
0.98
Current Ratio
1.05
Debt / Equity
0.71
LT Debt / Equity
0.03
-
-
EPS (TTM)
-1.26
EPS next Y
-
EPS next Q
-
EPS this Y
-553.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-18.35%
Revenue Q/Q
0.91%
EPS Q/Q
-220.63%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-25%
Inst Own
-
Inst Trans
-
ROA
-11%
ROE
-34%
ROC
-0.31%
Gross Margin
9%
Oper. Margin
-25%
Profit Margin
-25%
Payout
-26%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.05-3.97
52W High
-17.67%
52W Low
+23.5%
RSI
41
Rel Volume
0.74
Avg Volume
26.99M
Volume
19.93M
Perf Week
-16.55%
Perf Month
-5%
Perf Quarter
-24.92%
Perf Half Y
-30.23%
-
-
-
-
Beta
0.536
-
-
Volatility
0.19%, 0.17%
Prev Close
-3.14%
Price
2.47
Change
2.49%
002589.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 22.87 | 23.56 | 18.45 | 14.28 | 8.35 | |
| Net income per share | 0.86 | -0.29 | 0.42 | 0.26 | -1.18 | |
| Operating cash flow per share | -0.11 | 1.4 | 0.25 | 0.3 | 0.35 | |
| Free cash flow per share | -0.52 | 0.77 | -0.1 | -0.01 | 0.24 | |
| Cash per share | 2.25 | 3.36 | 3.92 | 2.58 | 2.88 | |
| Book value per share | 5.7 | 4.8 | 5.07 | 5.13 | 3.67 | |
| Tangible book value per share | 5.28 | 5.86 | 6.41 | 5.82 | 3.38 | |
| Share holders equity per share | 5.7 | 4.8 | 5.07 | 5.13 | 3.67 | |
| Interest debt per share | 5.53 | 4.89 | 6.86 | 3.27 | 2.93 | |
| Market cap | 10.2B | 11.43B | 7.66B | 5.78B | 6.07B | |
| Enterprise value | 14.75B | 13.18B | 11.45B | 5.47B | 4.65B | |
| P/E ratio | 7.99 | -26.28 | 12.27 | 15.13 | -3.49 | |
| Price to sales ratio | 0.3 | 0.32 | 0.28 | 0.27 | 0.49 | |
| POCF ratio | -60.23 | 5.46 | 21.01 | 13.05 | 11.61 | |
| PFCF ratio | -13.19 | 9.86 | -54.39 | -318.83 | 17.25 | |
| P/B Ratio | 1.21 | 1.59 | 1.03 | 0.76 | 1.12 | |
| PTB ratio | 1.21 | 1.59 | 1.03 | 0.76 | 1.12 | |
| EV to sales | 0.43 | 0.37 | 0.42 | 0.26 | 0.38 | |
| Enterprise value over EBITDA | 5.03 | 4.69 | 5.74 | 3.38 | -8.57 | |
| EV to operating cash flow | -87.09 | 6.29 | 31.41 | 12.35 | 8.89 | |
| EV to free cash flow | -19.07 | 11.36 | -81.3 | -301.75 | 13.21 | |
| Earnings yield | 0.13 | -0.04 | 0.08 | 0.07 | -0.29 | |
| Free cash flow yield | -0.08 | 0.1 | -0.02 | 0 | 0.06 | |
| Debt to equity | 0.9 | 0.91 | 1.28 | 0.56 | 0.72 | |
| Debt to assets | 0.22 | 0.2 | 0.3 | 0.16 | 0.21 | |
| Net debt to EBITDA | 1.55 | 0.62 | 1.9 | -0.19 | 2.62 | |
| Current ratio | 1.35 | 1.34 | 1.29 | 1.25 | 1.03 | |
| Interest coverage | 4.69 | 3.44 | 2.89 | 2.35 | 0.16 | |
| Income quality | -0.13 | -4.82 | 0.58 | 1.16 | -0.3 | |
| Dividend Yield | 0.05 | 0.04 | 0.04 | 0.05 | 0.03 | |
| Payout ratio | 0.4 | -1.15 | 0.54 | 0.83 | -0.09 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.1 | 0.05 | 0.03 | 0.04 | 0.04 | |
| Capex to operating cash flow | 3.57 | -0.45 | -1.39 | -1.04 | -0.33 | |
| Capex to revenue | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 | |
| Capex to depreciation | -2.58 | -3.4 | -1.75 | -1.44 | -0.6 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0.01 | |
| Graham number | 10.51 | 5.6 | 6.95 | 5.47 | 9.87 | |
| ROIC | 0.11 | -0.78 | 0.07 | 0.09 | 0.01 | |
| Return on tangible assets | 0.04 | -0.01 | 0.02 | 0.02 | -0.1 | |
| Graham Net | -1.53 | -0.8 | -0.21 | -0.98 | -2.04 | |
| Working capital | 7.39B | 7.1B | 5.93B | 4.16B | 351.12M | |
| Tangible asset value | 7.82B | 8.77B | 9.44B | 8.58B | 4.98B | |
| Net current asset value | 5.13B | 5.54B | 5.68B | 3.97B | 240.29M | |
| Invested capital | 0.9 | 0.91 | 1.28 | 0.56 | 0.72 | |
| Average receivables | 17.92B | 19.89B | 18.28B | 15.78B | 10.17B | |
| Average payables | 7.6B | 9.69B | 9.39B | 8.95B | 8.75B | |
| Average inventory | 4.24B | 4.07B | 3.29B | 2.5B | 1.51B | |
| Days sales outstanding | 224.86 | 195.46 | 237.14 | 240.57 | 191.68 | |
| Days payables outstanding | 116.06 | 136.89 | 133.24 | 207.52 | 264.67 | |
| Days of inventory on hand | 59.92 | 46.81 | 48.24 | 43.83 | 32.75 | |
| Receivables turnover | 1.62 | 1.87 | 1.54 | 1.52 | 1.9 | |
| Payables turnover | 3.14 | 2.67 | 2.74 | 1.76 | 1.38 | |
| Inventory turnover | 6.09 | 7.8 | 7.57 | 8.33 | 11.15 | |
| ROE | 0.15 | -0.06 | 0.08 | 0.05 | -0.32 | |
| Capex per share | -0.41 | -0.62 | -0.34 | -0.31 | -0.12 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.35 | 0.96 | 1.41 | 1.33 | 1.35 | |
| Net income per share | 0.01 | -1.28 | 0.02 | 0.01 | -0.01 | |
| Operating cash flow per share | 0.01 | -1.28 | 0.02 | 0.07 | 0.1 | |
| Free cash flow per share | -0.02 | -1.21 | 0.02 | 0.05 | 0.1 | |
| Cash per share | 4.03 | 2.88 | 4.74 | 4.19 | 3.72 | |
| Book value per share | 4.89 | 3.67 | 3.69 | 3.65 | 3.64 | |
| Tangible book value per share | 5.29 | 3.38 | 3.41 | 3.36 | 3.3 | |
| Share holders equity per share | 4.89 | 3.67 | 3.69 | 3.65 | 3.64 | |
| Interest debt per share | 3.99 | 2.7 | 3.82 | 2.93 | 2.64 | |
| Market cap | 5.8B | 6.07B | 5.81B | 5.12B | 5.31B | |
| Enterprise value | 5.65B | 4.65B | 4.43B | 3.31B | 3.67B | |
| P/E ratio | 196.92 | -0.81 | 48.43 | 134.52 | -116 | |
| Price to sales ratio | 1.73 | 4.29 | 2.8 | 2.55 | 2.62 | |
| POCF ratio | 787.67 | -3.22 | 193.73 | 49.6 | 34.52 | |
| PFCF ratio | -198.23 | -3.39 | 262.44 | 65.6 | 36.54 | |
| P/B Ratio | 0.83 | 1.12 | 1.07 | 0.93 | 0.97 | |
| PTB ratio | 0.83 | 1.12 | 1.07 | 0.93 | 0.97 | |
| EV to sales | 1.69 | 3.29 | 2.14 | 1.65 | 1.81 | |
| Enterprise value over EBITDA | 17.83 | -2.93 | 26.19 | 89.1 | 10.9 | |
| EV to operating cash flow | 767.53 | -2.47 | 147.69 | 32.04 | 23.85 | |
| EV to free cash flow | -193.17 | -2.6 | 200.07 | 42.38 | 25.25 | |
| Earnings yield | 0 | -0.31 | 0.01 | 0 | 0 | |
| Free cash flow yield | -0.01 | -0.29 | 0 | 0.02 | 0.03 | |
| Debt to equity | 0.8 | 0.72 | 1.01 | 0.8 | 0.71 | |
| Debt to assets | 0.23 | 0.21 | 0.29 | 0.24 | 0.22 | |
| Net debt to EBITDA | -0.47 | 0.9 | -8.16 | -48.81 | -4.88 | |
| Current ratio | 1.21 | 1.03 | 1.05 | 1.07 | 1.05 | |
| Interest coverage | 2.38 | -29.14 | 0.27 | 0.71 | -0.17 | |
| Income quality | 1 | 1 | 1 | 10.85 | -13.44 | |
| Dividend Yield | 0 | 0.03 | 0.02 | 0.01 | 0.02 | |
| Payout ratio | 1.66 | -0.1 | 4.6 | 6.05 | -8.32 | |
| Sales general and administrative to revenue | 0.12 | -0.17 | 0.05 | 0 | 0.12 | |
| Research and developement to revenue | 0 | 0.01 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Capex to operating cash flow | -4.97 | -0.05 | -0.26 | -0.24 | -0.06 | |
| Capex to revenue | -0.01 | 0.07 | 0 | -0.01 | 0 | |
| Capex to depreciation | -0.47 | 1.2 | -0.13 | -0.43 | 0.1 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | -0.01 | |
| Graham number | 0.75 | 10.27 | 1.3 | 0.72 | 0.79 | |
| ROIC | 0.01 | -0.2 | 0 | 0 | 0 | |
| Return on tangible assets | 0 | -0.11 | 0 | 0 | 0 | |
| Graham Net | -0.33 | -2.04 | -0.97 | -0.87 | -0.97 | |
| Working capital | 3.21B | 351.12M | 615.24M | 844.42M | 627.98M | |
| Tangible asset value | 7.53B | 4.98B | 5.02B | 5.05B | 4.97B | |
| Net current asset value | 3.06B | 240.29M | 547.02M | 686.97M | 413.08M | |
| Invested capital | 0.8 | 0.72 | 1.01 | 0.8 | 0.71 | |
| Average receivables | 12.01B | 8.78B | 6.3B | 6.03B | 5.82B | |
| Average payables | 8.01B | 7.73B | 7.35B | 7.13B | 7.17B | |
| Average inventory | 1.56B | 1.18B | 861.79M | 822.88M | 832.51M | |
| Days sales outstanding | 298.29 | 411.36 | 266.13 | 265.96 | 253.71 | |
| Days payables outstanding | 245.88 | 441.61 | 358.1 | 365.64 | 365.2 | |
| Days of inventory on hand | 44.6 | 54.64 | 39.48 | 44 | 40.78 | |
| Receivables turnover | 0.3 | 0.22 | 0.34 | 0.34 | 0.35 | |
| Payables turnover | 0.37 | 0.2 | 0.25 | 0.25 | 0.25 | |
| Inventory turnover | 2.02 | 1.65 | 2.28 | 2.05 | 2.21 | |
| ROE | 0 | -0.35 | 0.01 | 0 | 0 | |
| Capex per share | -0.03 | 0.06 | -0.01 | -0.02 | -0.01 |
002589.SZ Frequently Asked Questions
What is Realcan Pharmaceutical Group Co., Ltd. stock symbol ?
Realcan Pharmaceutical Group Co., Ltd. is a CN stock and trading under the symbol 002589.SZ
What is Realcan Pharmaceutical Group Co., Ltd. stock quote today ?
Realcan Pharmaceutical Group Co., Ltd. stock price is $2.47 today.
Is Realcan Pharmaceutical Group Co., Ltd. stock public?
Yes, Realcan Pharmaceutical Group Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 26.99M
- Market Capitalization 4.16B
- Employee 5.12K
- CEO Ms. Renhua Zhang
- Headquarters Yantai,CN
- IPO Date 2011-06-10
-
Website
https://www.realcan.cn 
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institution worldwide. It sells drugs, vaccines, and medical devices. The company also provides medical logistics services; third-party logistics services; disinfection and sterilization; and lease, and hospital logistics services for medical institutions. It serves drug distribution, academic services, medical diagnosis, financial technology, traditional Chinese medicine, digital medical care, professional logistics, and comprehensive equipment. The company was formerly known as Realcan Pharmaceutical Co., Ltd. and changed its name to Realcan Pharmaceutical Group Co., Ltd. in December 2018. Realcan Pharmaceutical Group Co., Ltd. was founded in 2004 and is based in Yantai, China.
